<DOC>
	<DOCNO>NCT01658020</DOCNO>
	<brief_summary>The purpose study Evaluate Efficacy Safety Profiles oral multiple dose Zabofloxacin Tablet 400 mg .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Profile Zabofloxacin Tablet 400mg Moxifloxacin Tablet 400mg</brief_title>
	<detailed_description>A Phase 3 , Multicenter , Double Blind , Active Controlled , Randomized Study Evaluate Efficacy Safety Zabofloxacin Patients acute bacterial exacerbation Chronic obstructive pulmonary disease .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Adult male female old age 40 Severity acute exacerbation Chronic obstructive pulmonary disease ( COPD ) must suit oral administration treatment Diagnosed COPD receive write informed consent outcome measure spirometry test confirm [ Ratio Forced Expiratory Volume 1 second ( FEV1 ) Forced Vital Capacity ( FVC ) ] ( FEV1/FVC ) &lt; 0.7 Subject show follow sign symptom : ( ) Purulent Sputum Sputum level increase ( ii ) Difficulty breathe increase Female subject might pregnant must pregnancy test result negative randomization do . She must receive write informed consent form ( NOTE : Subject use single hormone contraception pregnancy control 1 year Tubule ligation menopause exclude study ) Subject agree sign write informed consent form approve Institutional Review Board ( IRB ) participate study follow study requirement Subject administer excess daily dose antimicrobial/antibiotics past 72 hour receive write consent Diagnosed pneumonia take chest Xray past 48 hour receive write consent Diagnosed infectious disease diseases result complication receive write consent ( NOTE : Septic shock , Bronchiectasis , Lung abscess , Pneumonia , Active tuberculosis , Pulmonary malignancy , Cystic fibrosis , Empyema , Asthma ) Have kidney liver diseases correspond follow criterion : ( ) Creatinine Clearance ( CCr ) &lt; 50 mL/min ( ii ) Blood Urea Nitrogen ( BUN ) â‰¥ 30 mg/dl ( iii ) Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &gt; 3 x Upper Limit Normal ( ULN ) ( iv ) Total bilirubin &gt; 2 x ULN ( v ) Alkaline Phosphatase ( ALP ) &gt; 2 x ULN . Organic gastrointestinal disorder abnormal absorption problem condition past 6 month receive write consent ( NOTE : Active Crohn 's disease , active ulcerative colitis ) Diagnosed neutropenia absolute neutrophil count &lt; 1,000cells/mm3 ( NOTE : Even though subject neutrophil count &lt; 1,000cells/mm3 , acute infection , subject maybe possible participate ) Chronic Hepatitis B carrier Have proof subject Hepatitis C carrier Hepatitis C antibody Immunodeficiency diseases HIV positive , AIDS , Bone marrow transplant leukemia Have medical history hypersensitive reaction antibiotic fluoroquinolones Have medical history seizure administration antiseizure drug past 1 year receive write consent ( NOTE : Epilepsy , Convulsions , Myasthenia gravis ) Medical history ventricular arrhythmia Medical history QTc prolongation currently administer drug delay QTc interval ( NOTE : QTc prolongation mean QTc interval &gt; 450 msec ) Complex infection diseases effect study assessment need longterm antibiotic treatment exceed 7 day Subject participate Clinical trial Bioequivalence test past 30 day receive write consent Clinically significant observation consider unsuitable base medical judgement investigator current condition effect quality safety data</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Acute exacerbation Chronic obstructive pulmonary disease</keyword>
	<keyword>Acute Exacerbation</keyword>
	<keyword>Chronic obstructive pulmonary disease ( COPD )</keyword>
	<keyword>Zabofloxacin</keyword>
	<keyword>Moxifloxacin</keyword>
</DOC>